Week Ending April 12, 2021

Future outcomes and health needs of chronic hepatitis C patients after receiving antiviral therapy
https://onlinelibrary.wiley.com/doi/abs/10.1111/jan.14850″
“To study the future outcomes and health needs of chronic hepatitis C (CHC) patients after receiving direct‐acting antiviral (DAA) therapy based on the health promotion perspectives and cardiometabolic risks in a rural setting.”

Hepatitis C Treatment
“Improvements in hepatitis C treatment have introduced pan-genotypic treatments, which treat all HCV genotypes (virus strains) with one treatment, shorter treatment time averaging from 8 to 12 weeks for the majority of liver conditions with high cure rates of 95% to 100%.”

LEGACY Trial of Radioembolization Shows Practice-Changing Data in HCC
“Michael R. Charlton, MD, MBBS, professor of medicine, director of the Center for Liver Diseases, and codirector of the Transplant Institute at the University of Chicago Medicine, discusses the impact of the LEGACY trial investigating yttrium-90 radioembolization in patients with solitary, unresectable hepatocellular carcinoma (HCC).”

How Michigan Plans to Eliminate Hepatitis C
“Michigan’s state health leaders have laid out a plan to end hepatitis C as a health threat in the Great Lakes State. Through the “We Treat Hep C” initiative, launched April 1, they aim to promote universal hepatitis testing and make treatment with Mavyret, an oral tablet, more accessible.”